GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (OTCPK:NMLSF) » Definitions » Short Interest

NMLSF (Restart Life Sciences) Short Interest


View and export this data going back to 2013. Start your Free Trial

What is Restart Life Sciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Restart Life Sciences's Short Interest

For the Biotechnology subindustry, Restart Life Sciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Restart Life Sciences's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Short Interest falls into.



Restart Life Sciences Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. It is focus is on creating health foods that address the needs of this community. Its Flagship developments includes Autism Spectrum, Health-Related Foods, Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA).

Restart Life Sciences Headlines

From GuruFocus

Nova Mentis Announces Closing of Non-Brokered Financing

By PRNewswire PRNewswire 03-15-2022